National Health and Nutrition Examination Survey

Among participants aged 6-49 years in NHANES between 1999 and 2004 who were cytomegalovirus (CMV) IgG positive, had stored urine samples available, tested and found with urinary CMV shedding and sufficient DNA for genotyping.

Surplus urine from individuals aged 6 to 49 years who participated in NHANES years 1999 to 2004 and with urinary shedding (N=537).

DNA Extraction: DNA was extracted from urine specimens by treatment with the QIAamp MinElute Media kit (Qiagen, Valencia, CA) then processed with the Qiacube automated extractor (Qiagen, Valencia, CA), both following manufacturer’s instructions.

PCR: The detection of CMV DNA was performed with polymerase chain reaction (PCR) targeting the envelope glycoprotein gB and gH genes by Vries et al., and using the MX 3005P Real-time PCR System (Agilent Technologies, New Castle, DE).

Commercial reagents were used for all CMV detection. All QA/QC procedures recommended by the manufacturer were followed. The laboratory follows guidelines established by CDC Quality Management Systems (QMS) to ensure overall quality and consistency in diagnostic testing.

Data were submitted after all the testing on CMV genotyping was complete. The data were not edited.

Data Access: All data are publicly available.

There are six variables:

gB1: CMV gB1 variant (1=Positive, 2=Negative, 3=Insufficient DNA)

gB2: CMV gB2 variant (1=Positive, 2=Negative, 3=Insufficient DNA)

gB3: CMV gB3 variant (1=Positive, 2=Negative, 3=Insufficient DNA)

gB4: CMV gB4 variant (1=Positive, 2=Negative, 3=Insufficient DNA)

gH1: CMV gH1 variant (1=Positive, 2=Negative, 3=Insufficient DNA)

gH2: CMV gH2 variant (1=Positive, 2=Negative, 3=Insufficient DNA)